Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression
BackgroundMultiple sclerosis (MS) is a complex immune-mediated disorder influenced by genetic, environmental, and microbial factors. Recent research has focused on the gut microbiota’s role in MS, yet limited studies have examined the fungal microbiota (mycobiota) in this context.MethodsIn this stud...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625794/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849390939440676864 |
|---|---|
| author | Ane Otaegui-Chivite Ane Otaegui-Chivite Miriam Gorostidi-Aicua Miriam Gorostidi-Aicua Laura Martins-Almeida Laura Martins-Almeida Ainhoa Alberro Ainhoa Alberro Leire Romarate Idoia Mendiburu Idoia Mendiburu Amaya Álvarez de Arcaya Maialen Arruti Maialen Arruti Tamara Castillo-Triviño Tamara Castillo-Triviño Tamara Castillo-Triviño David Otaegui David Otaegui Laura Moles Laura Moles |
| author_facet | Ane Otaegui-Chivite Ane Otaegui-Chivite Miriam Gorostidi-Aicua Miriam Gorostidi-Aicua Laura Martins-Almeida Laura Martins-Almeida Ainhoa Alberro Ainhoa Alberro Leire Romarate Idoia Mendiburu Idoia Mendiburu Amaya Álvarez de Arcaya Maialen Arruti Maialen Arruti Tamara Castillo-Triviño Tamara Castillo-Triviño Tamara Castillo-Triviño David Otaegui David Otaegui Laura Moles Laura Moles |
| author_sort | Ane Otaegui-Chivite |
| collection | DOAJ |
| description | BackgroundMultiple sclerosis (MS) is a complex immune-mediated disorder influenced by genetic, environmental, and microbial factors. Recent research has focused on the gut microbiota’s role in MS, yet limited studies have examined the fungal microbiota (mycobiota) in this context.MethodsIn this study, we characterized the gut mycobiota of individuals with MS from the Basque Country, identifying specific fungal taxa associated with MS risk factors, clinical severity, and dietary patterns.ResultsOur results revealed higher fungal diversity and richness in MS patients compared to controls, with significant enrichment of certain genera, including Saccharomyces, Torulaspora, and Malassezia. Malassezia demonstrated a strong association with increased disability, aligning with its previous identification in neurodegenerative conditions. Furthermore, we found that the presence of the MS-associated allele HLA-DRB1*1501 significantly influenced mycobiota composition and correlated with disability metrics. Additionally, we observed a complex interplay between plasma biomarkers (chitotriosidase and calprotectin) and specific fungal groups, with disease-specific correlations indicating potential interactions between the immune response and gut fungi. Notably, dietary fats showed a greater impact on mycobiota composition in MS patients than in controls, highlighting altered lipid metabolism in MS.ConclusionThese findings provide new insights into the fungal component of the gut microbiota in MS and underscore its potential role in disease pathogenesis and progression. Our work suggests that fungal biomarkers, together with genetic and dietary factors, may help refine our understanding of MS and support the development of mycobiota-targeted therapies. |
| format | Article |
| id | doaj-art-0bd1f8dcaa9a4232b91770f5d9505fa7 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-0bd1f8dcaa9a4232b91770f5d9505fa72025-08-20T03:41:15ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16257941625794Exploring the mycobiota in multiple sclerosis: its influence on disease development and progressionAne Otaegui-Chivite0Ane Otaegui-Chivite1Miriam Gorostidi-Aicua2Miriam Gorostidi-Aicua3Laura Martins-Almeida4Laura Martins-Almeida5Ainhoa Alberro6Ainhoa Alberro7Leire Romarate8Idoia Mendiburu9Idoia Mendiburu10Amaya Álvarez de Arcaya11Maialen Arruti12Maialen Arruti13Tamara Castillo-Triviño14Tamara Castillo-Triviño15Tamara Castillo-Triviño16David Otaegui17David Otaegui18Laura Moles19Laura Moles20Group of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainNeurology Department, Hospital Universitario Donostia, Osakidetza Basque Health Service, San Sebastián, SpainNeurology Department, Hospital Universitario Araba, Osakidetza Basque Health Service, Vitoria, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainNeurology Department, Hospital Universitario Donostia, Osakidetza Basque Health Service, San Sebastián, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainNeurology Department, Hospital Universitario Donostia, Osakidetza Basque Health Service, San Sebastián, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainGroup of Neuroimmunilogy, Biogipuzkoa Health Research Institute, San Sebastián, SpainCenter for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, SpainBackgroundMultiple sclerosis (MS) is a complex immune-mediated disorder influenced by genetic, environmental, and microbial factors. Recent research has focused on the gut microbiota’s role in MS, yet limited studies have examined the fungal microbiota (mycobiota) in this context.MethodsIn this study, we characterized the gut mycobiota of individuals with MS from the Basque Country, identifying specific fungal taxa associated with MS risk factors, clinical severity, and dietary patterns.ResultsOur results revealed higher fungal diversity and richness in MS patients compared to controls, with significant enrichment of certain genera, including Saccharomyces, Torulaspora, and Malassezia. Malassezia demonstrated a strong association with increased disability, aligning with its previous identification in neurodegenerative conditions. Furthermore, we found that the presence of the MS-associated allele HLA-DRB1*1501 significantly influenced mycobiota composition and correlated with disability metrics. Additionally, we observed a complex interplay between plasma biomarkers (chitotriosidase and calprotectin) and specific fungal groups, with disease-specific correlations indicating potential interactions between the immune response and gut fungi. Notably, dietary fats showed a greater impact on mycobiota composition in MS patients than in controls, highlighting altered lipid metabolism in MS.ConclusionThese findings provide new insights into the fungal component of the gut microbiota in MS and underscore its potential role in disease pathogenesis and progression. Our work suggests that fungal biomarkers, together with genetic and dietary factors, may help refine our understanding of MS and support the development of mycobiota-targeted therapies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625794/fullmycobiomemultiple sclerosischitotriosidasecalprotectinHLA-DRB1*1501 |
| spellingShingle | Ane Otaegui-Chivite Ane Otaegui-Chivite Miriam Gorostidi-Aicua Miriam Gorostidi-Aicua Laura Martins-Almeida Laura Martins-Almeida Ainhoa Alberro Ainhoa Alberro Leire Romarate Idoia Mendiburu Idoia Mendiburu Amaya Álvarez de Arcaya Maialen Arruti Maialen Arruti Tamara Castillo-Triviño Tamara Castillo-Triviño Tamara Castillo-Triviño David Otaegui David Otaegui Laura Moles Laura Moles Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression Frontiers in Immunology mycobiome multiple sclerosis chitotriosidase calprotectin HLA-DRB1*1501 |
| title | Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression |
| title_full | Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression |
| title_fullStr | Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression |
| title_full_unstemmed | Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression |
| title_short | Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression |
| title_sort | exploring the mycobiota in multiple sclerosis its influence on disease development and progression |
| topic | mycobiome multiple sclerosis chitotriosidase calprotectin HLA-DRB1*1501 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625794/full |
| work_keys_str_mv | AT aneotaeguichivite exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT aneotaeguichivite exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT miriamgorostidiaicua exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT miriamgorostidiaicua exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT lauramartinsalmeida exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT lauramartinsalmeida exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT ainhoaalberro exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT ainhoaalberro exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT leireromarate exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT idoiamendiburu exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT idoiamendiburu exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT amayaalvarezdearcaya exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT maialenarruti exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT maialenarruti exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT tamaracastillotrivino exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT tamaracastillotrivino exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT tamaracastillotrivino exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT davidotaegui exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT davidotaegui exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT lauramoles exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression AT lauramoles exploringthemycobiotainmultiplesclerosisitsinfluenceondiseasedevelopmentandprogression |